Traded Apr 14, 2026 · largest single transaction ~$109K
Show all 2 transactions
Apr 14, 2026~$109K · 108K sh @ $1.00
DetailsOfficial recordApr 14, 2026~$2.1K · 2,000 sh @ $1.03
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ALZN · NASDAQ · Pharmaceutical Preparations
Alzamend Neuro (ALZN) · oqro.io/stocks/ALZN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.7758−0.2442 (−23.94%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
2 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Apr 14, 2026 · largest single transaction ~$109K
Apr 14, 2026~$109K · 108K sh @ $1.00
DetailsOfficial recordApr 14, 2026~$2.1K · 2,000 sh @ $1.03
DetailsOfficial recordInsider selling
Traded Aug 26 · filed 5 days laterNot reported under a pre-arranged trading plan
Since the trade −53.5% · S&P 500 −10.0% · to Nov 20
An Alzamend Neuro director sold $3.1K of Alzamend Neuro shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Dec 23, 2025 · filed 7 days laterNot reported under a pre-arranged trading plan
Since the trade −62.6% · S&P 500 +0.3% · to Nov 20
An Alzamend Neuro director sold $3.8K of Alzamend Neuro shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Dec 19, 2025 · filed 4 days laterNot reported under a pre-arranged trading plan
Since the trade −63.2% · S&P 500 +1.4% · to Nov 20
An Alzamend Neuro director sold $7.1K of Alzamend Neuro shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Oct 23, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −66.7% · S&P 500 +2.7% · to Nov 20
An Alzamend Neuro director sold $69 of Alzamend Neuro shares. The filing does not indicate a pre-arranged trading plan.
Traded Oct 6 – Oct 9, 2025 · largest single transaction ~$247KNot reported under a pre-arranged trading plan
Oct 8, 2025~$247K · 101K sh @ $2.44
DetailsTraded Sep 26 – Sep 30, 2025 · largest single transaction ~$88KNot reported under a pre-arranged trading plan
Sep 29, 2025~$88K · 38K sh @ $2.31
DetailsTraded Sep 19 – Sep 25, 2025 · largest single transaction ~$181KNot reported under a pre-arranged trading plan
Sep 23, 2025~$103K · 43K sh @ $2.38
DetailsTraded Sep 17 – Sep 18, 2025 · largest single transaction ~$51KNot reported under a pre-arranged trading plan
Sep 18, 2025~$51K · 21K sh @ $2.47
DetailsTraded Jul 25 – Jul 31, 2025 · largest single transaction ~$222KNot reported under a pre-arranged trading plan
Jul 31, 2025~$222K · 100K sh @ $2.22
DetailsTraded Jul 23 – Jul 24, 2025 · largest single transaction ~$176KNot reported under a pre-arranged trading plan
Jul 23, 2025~$176K · 60K sh @ $2.95
DetailsTraded May 12, 2025 · largest single transaction ~$6.1KNot reported under a pre-arranged trading plan
May 12, 2025~$58 · 11 sh @ $5.28
DetailsInsider buying
Traded Mar 26, 2025 · filed 1 day later
Since the trade −91.4% · S&P 500 +21.3% · to Nov 20
An Alzamend Neuro director paid $3.3K out of pocket for Alzamend Neuro shares. 2 other people at Alzamend Neuro bought some too, in the same month. Shares held went up 13% with this purchase.
Insider buying
Traded Mar 21, 2025 · filed 4 days later
Since the trade −91.5% · S&P 500 +22.3% · to Nov 20
An Alzamend Neuro director paid $3K out of pocket for Alzamend Neuro shares. 2 other people at Alzamend Neuro bought some too, in the same month.
Insider buying
Traded Mar 21, 2025 · filed 3 days later
Since the trade −91.5% · S&P 500 +22.3% · to Nov 20
The CFO of Alzamend Neuro paid $5K out of pocket for Alzamend Neuro shares. 2 other people at Alzamend Neuro bought some too, in the same month. Shares held went up 926% with this purchase.
Traded Mar 18 – Mar 20, 2025 · largest single transaction ~$4.9K
Mar 20, 2025~$4.9K · 5,000 sh @ $0.9783
DetailsOfficial recordInsider buying
Traded Mar 18, 2025 · filed the same day
Since the trade −90.8% · S&P 500 +23.0% · to Nov 20
An Alzamend Neuro director paid $4.8K out of pocket for Alzamend Neuro shares. 2 other people at Alzamend Neuro bought some too, in the same month. Shares held went up 7% with this purchase.
Insider buying
Traded Mar 12, 2025 · filed 2 days later
Since the trade −87.1% · S&P 500 +23.4% · to Nov 20
An Alzamend Neuro director paid $68 out of pocket for Alzamend Neuro shares. 2 other people at Alzamend Neuro bought some too, in the same month.
Oct 9, 2025~$47K · 20K sh @ $2.32
DetailsOfficial recordOct 6, 2025~$201K · 82K sh @ $2.45
DetailsOfficial recordOct 7, 2025~$143K · 57K sh @ $2.49
DetailsOfficial recordSep 26, 2025~$87K · 38K sh @ $2.31
DetailsOfficial recordSep 30, 2025~$8.3K · 3,566 sh @ $2.33
DetailsOfficial recordSep 24, 2025~$90K · 39K sh @ $2.31
DetailsOfficial recordSep 25, 2025~$34K · 15K sh @ $2.31
DetailsOfficial recordSep 19, 2025~$181K · 77K sh @ $2.35
DetailsOfficial recordSep 17, 2025~$5.2K · 2,121 sh @ $2.45
DetailsOfficial recordJul 30, 2025~$74K · 29K sh @ $2.51
DetailsOfficial recordJul 25, 2025~$106K · 37K sh @ $2.90
DetailsOfficial recordJul 28, 2025~$22K · 8,311 sh @ $2.68
DetailsOfficial recordJul 24, 2025~$28K · 9,621 sh @ $2.93
DetailsOfficial recordMay 12, 2025~$6.1K · 1,213 sh @ $5.06
DetailsOfficial recordMar 18, 2025~$4.9K · 5,000 sh @ $0.9703
DetailsOfficial record9 open-market purchases and 25 open-market sales by insiders of ALZN between Feb 14, 2023 and today, placed against the company's last 3 earnings releases. The latest on file was filed Jul 23, 2025. The data provider lists the next release for Dec 7, 2026; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Jul 23, 2025 | None | 1 sale | 5 sales |
| Dec 12, 2024 | None | None | None |
| Mar 16, 2023 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies